Today’s guest is Karl Pfleger. After spending a decade as one of the first AI researchers at Google from 2002 to 2011, he has dedicated himself to the cause of rejuvenation biotechnology for nearly a decade. He is a philanthropist, community builder, and prolific angel investor with over 35 investments into rejuvenation biotech startups. His website, agingbiotech.info, provides valuable information to the entire field, and his talks and X posts are highly insightful and influential within longevity. 

Karl has deeply researched and nuanced takes, and those really show in this conversation. We’ll cover why epigenetic reprogramming won’t solve aging, Karl’s investment strategy and what distinguishes true rejuvenation technology, and why better diagnostic technologies could be the key to personalized aging interventions.